Beam Therapeutics Inc. (BEAM): Price and Financial Metrics
GET POWR RATINGS... FREE!
BEAM POWR Grades
- BEAM scores best on the Growth dimension, with a Growth rank ahead of 76.42% of US stocks.
- The strongest trend for BEAM is in Stability, which has been heading down over the past 179 days.
- BEAM's current lowest rank is in the Stability metric (where it is better than 2.61% of US stocks).
BEAM Stock Summary
- Of note is the ratio of Beam Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 4.98% of US stocks have a lower such ratio.
- BEAM's price/sales ratio is 82.23; that's higher than the P/S ratio of 97.3% of US stocks.
- As for revenue growth, note that BEAM's revenue has grown 215,916.7% over the past 12 months; that beats the revenue growth of 100% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Beam Therapeutics Inc are CRSP, ETON, VTVT, LPCN, and PLXP.
- Visit BEAM's SEC page to see the company's official filings. To visit the company's web site, go to www.beamtx.com.
BEAM Valuation Summary
- In comparison to the median Healthcare stock, BEAM's price/sales ratio is 8069636.84% higher, now standing at 306650.
- Over the past 19 months, BEAM's price/sales ratio has gone NA NA.
- BEAM's price/sales ratio has moved NA NA over the prior 19 months.
Below are key valuation metrics over time for BEAM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BEAM | 2021-08-31 | 306650.0 | 13.4 | -18.1 | -17.8 |
| BEAM | 2021-08-30 | 295508.3 | 12.9 | -17.4 | -17.2 |
| BEAM | 2021-08-27 | 294654.2 | 12.9 | -17.3 | -17.1 |
| BEAM | 2021-08-26 | 280829.2 | 12.3 | -16.5 | -16.3 |
| BEAM | 2021-08-25 | 282016.7 | 12.3 | -16.6 | -16.4 |
| BEAM | 2021-08-24 | 296779.2 | 13.0 | -17.5 | -17.3 |
BEAM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BEAM has a Quality Grade of D, ranking ahead of 6.52% of graded US stocks.
- BEAM's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows BEAM's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0 | 1 | -0.966 |
| 2021-03-31 | 0 | 1 | -1.254 |
| 2020-12-31 | 0 | 1 | -1.054 |
| 2020-09-30 | 0 | 1 | -0.896 |
| 2019-12-31 | 0 | 1 | -1.360 |
BEAM Price Target
For more insight on analysts targets of BEAM, see our BEAM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $123.57 | Average Broker Recommendation | 1.36 (Strong Buy) |
BEAM Stock Price Chart Interactive Chart >
BEAM Price/Volume Stats
| Current price | $35.19 | 52-week high | $138.52 |
| Prev. close | $33.94 | 52-week low | $27.77 |
| Day low | $31.58 | Volume | 1,198,500 |
| Day high | $35.86 | Avg. volume | 1,142,489 |
| 50-day MA | $47.43 | Dividend yield | N/A |
| 200-day MA | $75.16 | Market Cap | 2.47B |
Beam Therapeutics Inc. (BEAM) Company Bio
Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.
Latest BEAM News From Around the Web
Below are the latest news stories about Beam Therapeutics Inc that investors may wish to consider to help them evaluate BEAM as an investment opportunity.
10 Genomics Stocks in Cathie Wood’s Portfolio That Are UnderperformingIn this article, we discuss 10 genomics stocks in Cathie Wood’s portfolio that are underperforming. If you want to skip our detailed analysis of these stocks, go directly to 5 Genomics Stocks in Cathie Wood’s Portfolio That Are Underperforming. ARK Investment Management is an innovation-focused hedge fund that is headquartered in St. Petersburg, Florida, with […] |
Top 10 Biotech Stocks to Buy According to Jeremy Green’s Redmile GroupIn this article, we will discuss the top 10 biotech stocks to buy according to Jeremy Green’s Redmile Group. If you want to skip our detailed analysis of Green’s history, investment philosophy performance, you can go directly to the Top 5 Biotech Stocks to Buy According to Jeremy Green’s Redmile Group. Jeremy Green is the […] |
Beam Therapeutics Inc. (NASDAQ: BEAM) Has Fallen -114.43% From Its Highs, What Comes Next?Beam Therapeutics Inc. (NASDAQ:BEAM)’s traded shares stood at 1.13 million during the last session. At the close of trading, the stock’s price was $64.60, to imply a decrease of -5.56% or -$3.8 in intraday trading. The BEAM share’s 52-week high remains $138.52, putting it -114.43% down since that peak but still an impressive 12.79% since … Beam Therapeutics Inc. (NASDAQ: BEAM) Has Fallen -114.43% From Its Highs, What Comes Next? Read More » |
Beam Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare ConferenceCAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the SVB Leerink 11 th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 9:20 a.m. ET. |
Why Pfizer's Deal With Beam Therapeutics Is a Smart MovePfizer (NYSE: PFE) recently announced a collaboration with Beam Therapeutics (NASDAQ: BEAM) to develop gene-editing therapies targeting rare genetic diseases. In this Motley Fool Live video, recorded on Jan. 12., Fool contributors Keith Speights and Brian Orelli discuss why Pfizer's deal with Beam appears to be a smart move. Keith Speights: We mentioned this on Monday I believe, that Pfizer had announced a collaboration with Beam Therapeutics to develop therapies targeting rare genetic diseases. |
BEAM Price Returns
| 1-mo | -16.49% |
| 3-mo | -45.98% |
| 6-mo | -57.04% |
| 1-year | -51.54% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -55.84% |
| 2021 | -2.39% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...